The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastomaMatthew McCord, Craig Horbinski|Neuro-Oncology|2024Cited by 8
A decade of the Oesophageal Cancer Clinical and Molecular Stratification ConsortiumChristopher J. Peters, Hannah Coles, Helen G. Coleman et al.|Nature Medicine|2023Cited by 5